On May 24, 2024, pharmaceutical giantEli Lilly and Companyannounced that it isinvestinga further $5.3 billion for the manufacturing of active pharmaceutical ingredients (API) for tirzepatide and pipeline medicines.
The company has already invested over $18 billion in new facilities in America and Europe, including $3.7 billion on its new manufacturing site in Lebanon, Indiana. The most recent investment will take the Indiana site’s funds to a total of $9 billion.
Lilly’s Newest Indiana Manufacturing Site
In 2023, Lilly started working on its newest manufacturing facility in theLEAPResearch and Innovation District, Lebanon, Indiana, converting a large part of the almost 600-acre complex into a construction site.
The facility will offer 200 full-time jobs for professionals like scientists and engineers, as well as operating and lab staff. The construction alone will provide over 5,000 jobs. When it’s up and running—which the company hopes will be in the last quarter of 2026—there will be around 900 people working there.
Lilly’s Investments
Further to successful research results on tirzepatide, also known as Mounjaro® (approved for diabetes in 2022) and Zepbound® (approved for obesity in 2023), Lilly started ramping up investments in new manufacturing facilities in the USA and Europe in 2020.
The company has since coughed up over $16 billion, with a further $1.2 billion used to update and renovate existing facilities in Indianapolis. Monies were put towards new locations in Concord, North Carolina, Limerick inIreland, and Alzey in Germany. The company also bought a manufacturing facility fromNexus Pharmaceuticalsin Pleasant Prairie, Wisconsin, for injectables.
Mounjaro® and Zepbound® (Tirzepatide)
Although risky, Lilly made these investments so that once Mounjaro® and Zepbound® were approved, the company would be ready to make thedrugsreadily available to those with type 2 diabetes and obesity. Since 2020, demand for these meds has greatly risen. The company plans to ramp up production from the new facility’s planned opening in 2026 to 2028.
These medicines are the only approved drugs available that activate the GIP and GLP-1 incretin hormone receptors. Thanks to the company’s expansion, Lilly will be able to increase its capacity to make the APIs needed for both these injections, as well as pipeline medicines.
Indiana’s Support
TheState of Indianawill partner up with Lilly to find the best utility and infrastructure solutions, including improvements to roads. It will also help the company raise capital, and plans to contribute land for a new learning and training center at LEAP—although this is still pending approval.
News of this new training center comes pursuant to Lilly’s investments in several training programs and scholarships atIvy Tech Community College,Purdue University, and Indiana’s 50-acre tech hub, the16 Tech Innovation District.
Image Credit: Shutterstock/oleschwander
